Primary regulatory
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed 2026-07-12.
U.S. Food and Drug AdministrationAccessed 2026-07-12
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
research-reta-02- Source code
- RETA-02
Source usage
Linked from 11 pages
Compound
Retatrutide
Video auditUnapproved Weight-Loss Drug 'Reta' Sold Online Despite Safety Concerns
Video auditRetatrutide Masterclass: How To Use It Optimally (Dose, Frequency, Diet, Exercise, & Supplements)
Video auditPeptides: The Science, Uses & Safety | Dr. Abud Bakri
Video auditRetatrutide Masterclass (the 'how to' for EVERYTHING) - Dr Trevor Bachmeyer
Video auditWhat Ozempic & Weight Loss Drugs Really Do to the Body
Video auditSafety Concerns Over Doctors Prescribing an Experimental Weight-Loss Drug
Video auditNew Data Released on Weight-Loss Drug Retatrutide
Video auditI Almost Died From a Fake Weight-Loss Injection
Video auditUnapproved Weight-Loss Drug Sparks Black-Market Concerns
Evidence curationBest Peptides for Weight Loss
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.